FDA recommends authorizing Pfizer COVID-19 vaccine for use in 5-11 age group

A Food and Drug Administration advisory committee today voted to recommend an emergency use authorization of Pfizer’s COVID-19 vaccine for children age 5-11. The agency’s Vaccines and Related Biological Products Advisory Committee, by a 17-1 vote, agreed that the available evidence justifies the administration of two 10-microgram doses, administered three weeks apart, particularly among those at the highest risk of severe COVID-19.